HK1086193A1 - Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4- - Google Patents

Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-

Info

Publication number
HK1086193A1
HK1086193A1 HK06107310.2A HK06107310A HK1086193A1 HK 1086193 A1 HK1086193 A1 HK 1086193A1 HK 06107310 A HK06107310 A HK 06107310A HK 1086193 A1 HK1086193 A1 HK 1086193A1
Authority
HK
Hong Kong
Prior art keywords
prevention
treatment
breast cancer
hydroxy tamoxifen
tamoxifen
Prior art date
Application number
HK06107310.2A
Other languages
English (en)
Chinese (zh)
Inventor
Dominique Salin-Drouin
Jacques Wepierre
Philippe Rouanet
Original Assignee
Besins Healthcare Lu Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Lu Sarl filed Critical Besins Healthcare Lu Sarl
Publication of HK1086193A1 publication Critical patent/HK1086193A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
HK06107310.2A 2003-04-01 2006-06-28 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4- HK1086193A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45896303P 2003-04-01 2003-04-01
PCT/EP2003/015029 WO2004087123A1 (en) 2003-04-01 2003-12-15 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
HK1086193A1 true HK1086193A1 (en) 2006-09-15

Family

ID=33131847

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06107310.2A HK1086193A1 (en) 2003-04-01 2006-06-28 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-
HK08113909.5A HK1119950A1 (en) 2003-04-01 2006-06-28 Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK08113909.5A HK1119950A1 (en) 2003-04-01 2006-06-28 Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-

Country Status (12)

Country Link
US (2) US7704516B2 (he)
EP (3) EP1952810B1 (he)
JP (1) JP5490346B2 (he)
AU (1) AU2003294973B2 (he)
CA (1) CA2519980C (he)
ES (3) ES2483896T3 (he)
HK (2) HK1086193A1 (he)
IL (1) IL170807A (he)
MX (1) MXPA05010597A (he)
NO (1) NO333805B1 (he)
NZ (1) NZ542499A (he)
WO (1) WO2004087123A1 (he)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4938237B2 (ja) * 2002-12-18 2012-05-23 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房痛の治療
EP1572171B1 (en) * 2002-12-18 2009-04-22 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
EP1952810B1 (en) * 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Treatment of breast cancer with 4-hydroxytamoxifen
WO2004110420A1 (en) * 2003-06-09 2004-12-23 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
ATE391499T1 (de) * 2004-03-22 2008-04-15 Besins Int Lab 4-hydroxytamoxifen zur behandlung und prophylaxe von benignen brusterkrankungen
EP1579857A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
EP1799201B1 (en) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
WO2015175561A1 (en) 2014-05-12 2015-11-19 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen and metabolites thereof by mass spectrometry
KR101571098B1 (ko) 2014-07-16 2015-11-23 건국대학교 산학협력단 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물
KR102178215B1 (ko) * 2014-08-27 2020-11-12 도요보 가부시키가이샤 저유전 접착제 조성물
WO2016094854A2 (en) * 2014-12-12 2016-06-16 Miradx Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
JP7131773B2 (ja) * 2016-04-29 2022-09-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ホルモン受容体に関連する転写活性の標的尺度
AU2018329202B2 (en) 2017-09-11 2022-10-27 Atossa Therapeutics, Inc. Methods for making and using endoxifen
US20210009865A1 (en) 2018-03-07 2021-01-14 Toagosei Co., Ltd. Adhesive composition, and adhesive layer-equipped layered product using same
WO2020023616A1 (en) * 2018-07-24 2020-01-30 Cornell University Methods of upregulating tiparp as anticancer strategies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
DE3781546D1 (de) * 1987-04-21 1992-10-08 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-beta-dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en.
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (he) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
ES2156361T5 (es) * 1996-03-29 2012-12-26 Keyvest Gmbh Cosmético o bien composición cosmética para el alisado y la tersura de la piel en el caso de tejido adiposo afectado, en especial en el caso de la "celulitis"
WO1999033451A2 (en) 1997-12-23 1999-07-08 Hexal Ag Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
ES2239057T3 (es) 1999-12-16 2005-09-16 Dermatrends, Inc. Agentes de liberacion de hidroxido utilizados como potenciadores de la permeacion cutanea.
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002340120A1 (en) 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
ES2330188T3 (es) * 2001-12-07 2009-12-07 Besins Manufacturing Belgium Composicion farmaceutica en forma de gel o de solucion a base de dihidrotestoterona, su procedimiento de preparacion y sus utilizaciones.
EP1572171B1 (en) * 2002-12-18 2009-04-22 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
JP4938237B2 (ja) * 2002-12-18 2012-05-23 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房痛の治療
EP1952810B1 (en) 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Treatment of breast cancer with 4-hydroxytamoxifen
WO2004110420A1 (en) * 2003-06-09 2004-12-23 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579857A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
NO20054526L (no) 2005-09-30
HK1119950A1 (en) 2009-03-20
EP1608353A1 (en) 2005-12-28
CA2519980A1 (en) 2004-10-14
WO2004087123A1 (en) 2004-10-14
AU2003294973A1 (en) 2004-10-25
NZ542499A (en) 2008-10-31
JP2006514967A (ja) 2006-05-18
ES2483896T3 (es) 2014-08-08
US20090186944A1 (en) 2009-07-23
US8475814B2 (en) 2013-07-02
ES2456957T3 (es) 2014-04-24
AU2003294973B2 (en) 2010-05-13
IL170807A (he) 2014-08-31
EP1952810A1 (en) 2008-08-06
US20050031695A1 (en) 2005-02-10
JP5490346B2 (ja) 2014-05-14
EP1608353B1 (en) 2014-04-30
CA2519980C (en) 2012-04-10
EP1941871A1 (en) 2008-07-09
EP1941871B1 (en) 2014-01-08
ES2456958T3 (es) 2014-04-24
MXPA05010597A (es) 2006-03-09
EP1952810B1 (en) 2014-01-08
US7704516B2 (en) 2010-04-27
NO333805B1 (no) 2013-09-16

Similar Documents

Publication Publication Date Title
HK1086193A1 (en) Prevention and treatment of breast cancer with 4-hydroxy tamoxifen 4-
EP1872124A4 (en) DIAGNOSTIC MARKERS FOR THE TREATMENT AND EVOLUTION OF BREAST CANCER AND METHODS OF USE
EP1968607A4 (en) TREATMENT OF CANCER AND OTHER DISEASES
IL166475A0 (en) Improved treatment of cancer with glutamine
EP1667680A4 (en) COMBINED METHODS OF TREATING CANCER
EP1663259A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP1565187A4 (en) CANCER TREATMENT METHODS AND RELATED METHODS
EP1816996A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING PLANT EXTRACTS FOR THE TREATMENT OF CANCER
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1812596A4 (en) TREATMENT OF CANCER AND COMPOSITIONS
EP1737472A4 (en) EFFECTIVE TREATMENT OF TUMORS AND CANCER USING TRICIRIBIN AND ASSOCIATED COMPOUNDS
EP1756166A4 (en) DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP1587837A3 (en) Prostate cancer diagnosis and treatment
AU2003296757A8 (en) Reduction of breast density with 4-hydroxy tamoxifen
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
EP1635694A4 (en) PROCESS FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF BREAST CANCER
GB0326578D0 (en) Cancer diagnosis and therapy
AU2003293130A8 (en) Methods for identifying risk of breast cancer and treatments thereof
AU2003231803A8 (en) Treatment of cancer with mefloquire
GB0329416D0 (en) Treatment of cancer
EP1409734A4 (en) DIAGNOSIS AND TREATMENT OF CANCER
EP1766051A4 (en) METHOD FOR IDENTIFYING BREAST CANCER RISK AND TREATMENTS THEREOF
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
IL175774A0 (en) Use of siramesine in the treatment of cancer

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20231216